Emily Crossley, CEO of Duchenne UK, explained what the money will go towards this year.
“We’re focused on clinical trials, on looking at repurposed drugs—ones that already exist and are approved for use for another disease.” Pre-clinical trials in the use of Simvastatin (commonly used to reduce cholesterol) have indicated that it may well reduce skeletal muscle damage and enhance muscle function. While this won’t cure the cause of DMD, it could do a lot to improve the lives of the children affected.
The benefit of using repurposed drugs is that the enormously expensive development stages and safety trials are already out of the way.
“We’re also setting up a clinical research hub. We’ve already funded sixteen posts with other charities,” added Emily. The need for this research network, which links health professionals around the country, became apparent when Duchenne UK realised that clinical trials were being turned away by the NHS because there were not enough doctors and nurses to carry them out.